Ever Supreme Bio Technology
Ever Supreme Biotechnology is a leading biotech company in Taiwan focused on immune cell and stem cell-based therapies. Its lead program, CAR001, is the first allogeneic, mRNA-engineered BiTE-secreting CAR-γδT therapy for solid tumors. CAR001 has IND approvals in the US and Taiwan and is now in Phase I/IIa trials (NCT06150885), with early signs of efficacy and no safety concerns in MSS CRC patients. Preclinical results were published in Advanced Science, showing potent anti-tumor activity.
In parallel, Ever Supreme is advancing an in vivo CAR-T platform that uses engineered extracellular vesicles to deliver CAR.BiTE DNA directly to T cells without viral vectors. This non-invasive, in-body programming approach has shown effective gene delivery and tumor control in solid tumor models, representing a promising innovation in next-generation immunotherapy.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}